PMID- 26415137
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20180524
IS  - 2151-4658 (Electronic)
IS  - 2151-464X (Linking)
VI  - 68
IP  - 5
DP  - 2016 May
TI  - Association of Lupus Anticoagulant With Long-Term Damage Accrual in 
      Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
PG  - 711-5
LID - 10.1002/acr.22723 [doi]
AB  - OBJECTIVE: Antiphospholipid antibodies (aPL) are frequently present in 
      antineutrophil cytoplasmic antibody-associated vasculitis (AAV) patients; 
      however, the prognostic impact of aPL in such patients has not been elucidated. 
      The objective of this study was to determine whether persistent aPL positivity in 
      AAV patients was associated with increased long-term damage accrual. METHODS: 
      Clinical data were retrospectively collected on all AAV patients who attended the 
      vasculitis clinic at our center over a 4-year period. Data collection included 
      presence of lupus anticoagulant (LAC) and IgG and IgM anticardiolipin (aCL) 
      antibody titers, along with concurrent diagnosis of antiphospholipid syndrome 
      (APS). Accumulation of long-term damage was quantified using the Vasculitis 
      Damage Index (VDI). RESULTS: Data from 116 AAV patients were analyzed. A total of 
      34% (n = 40) had persistently positive aCL or LAC or a concurrent diagnosis of 
      APS and were classified as AAV/aPL. A total of 76 patients (66%) were classified 
      as AAV alone. LAC was present in a statistically higher proportion of AAV/aPL 
      patients than those in the AAV-alone group (P < 0.0001). Mean VDI score was 
      significantly higher in the AAV/aPL group at mean +/- SD 3.54 +/- 1.36 as compared to 
      1.96 +/- 1.42 in the AAV-alone group (P < 0.0001). Major vascular damage scores 
      were significantly higher in the AAV/aPL group, with mean +/- SD 0.32 +/- 0.59 as 
      compared to 0.07 +/- 0.26 in the AAV-alone group (P < 0.007). CONCLUSION: 
      Persistently positive occurrence of aPL, in particular LAC, is present in a 
      significant proportion of AAV patients and is associated with a higher VDI score. 
      Clinicians should consider screening AAV patients for aPL.
CI  - (c) 2016, American College of Rheumatology.
FAU - Jordan, Natasha
AU  - Jordan N
AD  - Guy's and St. Thomas' National Health Service Foundation Trust, London, UK.
FAU - D'cruz, David P
AU  - D'cruz DP
AD  - Guy's and St. Thomas' National Health Service Foundation Trust, London, UK.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Arthritis Care Res (Hoboken)
JT  - Arthritis care & research
JID - 101518086
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulin M)
RN  - 0 (Lupus Coagulation Inhibitor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated 
      Vasculitis/*blood/immunology/pathology
MH  - Antibodies, Anticardiolipin/blood/immunology
MH  - Antibodies, Antineutrophil Cytoplasmic/blood/immunology
MH  - Antibodies, Antiphospholipid/blood/immunology
MH  - Antiphospholipid Syndrome/*blood/immunology
MH  - Blood Vessels/immunology/pathology
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/blood/immunology
MH  - Immunoglobulin M/blood/immunology
MH  - Lupus Coagulation Inhibitor/*blood/immunology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Time
EDAT- 2015/09/29 06:00
MHDA- 2017/08/02 06:00
CRDT- 2015/09/29 06:00
PHST- 2015/02/20 00:00 [received]
PHST- 2015/08/17 00:00 [revised]
PHST- 2015/09/08 00:00 [accepted]
PHST- 2015/09/29 06:00 [entrez]
PHST- 2015/09/29 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
AID - 10.1002/acr.22723 [doi]
PST - ppublish
SO  - Arthritis Care Res (Hoboken). 2016 May;68(5):711-5. doi: 10.1002/acr.22723.